文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于免疫微环境调节的骨肉瘤免疫治疗

Immunotherapy of osteosarcoma based on immune microenvironment modulation.

作者信息

Lian Heping, Zhang Jiakui, Hou Shuna, Ma Shuang, Yu Jiachen, Zhao Wei, Zhao Duoyi, Zhang Zhiyu

机构信息

Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.

出版信息

Front Immunol. 2025 Jan 23;15:1498060. doi: 10.3389/fimmu.2024.1498060. eCollection 2024.

DOI:10.3389/fimmu.2024.1498060
PMID:39916962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11799554/
Abstract

Osteosarcoma is a highly malignant tumor with unsatisfactory therapeutic outcomes achieved by chemotherapy, radiotherapy, and surgery. As an emerging oncological treatment, immunotherapy has shown potential in the clinical management of many tumors but has a poor response rate in osteosarcoma. The immunosuppressive microenvironment in osteosarcoma is the main reason for the ineffectiveness of immunotherapy, in which the low immune response rate of immune effector cells and the high activation of immunosuppressive cells contribute to this outcome. Therefore, modulating the function of the immune microenvironment in osteosarcoma is expected to remodel the immunosuppressive microenvironment of osteosarcoma and enhance the efficacy of immunotherapy. This article reviews the role of immune cells in the progression of osteosarcoma, describes the corresponding regulatory tools for the characteristics of different cells to enhance the efficacy of osteosarcoma immunotherapy, and concludes the prospects and future challenges of osteosarcoma immunotherapy.

摘要

骨肉瘤是一种高度恶性的肿瘤，化疗、放疗和手术治疗效果均不理想。作为一种新兴的肿瘤治疗方法，免疫疗法在许多肿瘤的临床治疗中显示出潜力，但在骨肉瘤中的反应率较低。骨肉瘤中的免疫抑制微环境是免疫疗法无效的主要原因，其中免疫效应细胞的低免疫反应率和免疫抑制细胞的高激活导致了这一结果。因此，调节骨肉瘤免疫微环境的功能有望重塑骨肉瘤的免疫抑制微环境并提高免疫疗法的疗效。本文综述了免疫细胞在骨肉瘤进展中的作用，描述了针对不同细胞特征提高骨肉瘤免疫治疗疗效的相应调控手段，并总结了骨肉瘤免疫治疗的前景和未来挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/1dac013604f3/fimmu-15-1498060-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/c30834323607/fimmu-15-1498060-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/7791a8a2e65d/fimmu-15-1498060-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/ebe128ae1306/fimmu-15-1498060-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/20a220cf0f91/fimmu-15-1498060-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/ba69f12467d1/fimmu-15-1498060-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/05bf6643b957/fimmu-15-1498060-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/bd04c29d142a/fimmu-15-1498060-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/485e5b01e72d/fimmu-15-1498060-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/1dac013604f3/fimmu-15-1498060-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/c30834323607/fimmu-15-1498060-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/7791a8a2e65d/fimmu-15-1498060-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/ebe128ae1306/fimmu-15-1498060-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/20a220cf0f91/fimmu-15-1498060-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/ba69f12467d1/fimmu-15-1498060-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/05bf6643b957/fimmu-15-1498060-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/bd04c29d142a/fimmu-15-1498060-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/485e5b01e72d/fimmu-15-1498060-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25cb/11799554/1dac013604f3/fimmu-15-1498060-g009.jpg

相似文献

[1]
Immunotherapy of osteosarcoma based on immune microenvironment modulation.

Front Immunol. 2025-1-23

[2]
Advances on immunotherapy for osteosarcoma.

Mol Cancer. 2024-9-9

[3]
New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.

Front Immunol. 2025-1-17

[4]
Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma.

Front Immunol. 2025-1-22

[5]
Biomaterials-Boosted Immunotherapy for Osteosarcoma.

Adv Healthc Mater. 2024-9

[6]
The origin and polarization of Macrophages and their role in the formation of the Pre-Metastatic niche in osteosarcoma.

Int Immunopharmacol. 2025-3-26

[7]
A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.

Front Immunol. 2024

[8]
Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.

Front Immunol. 2025-3-18

[9]
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.

J Immunother Cancer. 2021-5

[10]
Osteosarcoma-targeting Pt prodrug amphiphile for enhanced chemo-immunotherapy via Ca trapping.

Acta Biomater. 2025-1-24

引用本文的文献

[1]
LncSNHGs: new targets in osteosarcoma.

Cancer Gene Ther. 2025-8-16

[2]
Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.

J Funct Biomater. 2025-6-5

本文引用的文献

[1]
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer.

Cancer Metastasis Rev. 2024-12-3

[2]
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.

Eur J Haematol. 2025-3

[3]
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.

Haematologica. 2025-3-1

[4]
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.

JAMA. 2024-12-10

[5]
Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.

Mol Ther. 2024-7-3

[6]
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Sci Adv. 2023-9-22

[7]
Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity.

Nat Commun. 2023-9-15

[8]
A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration.

J Control Release. 2023-3

[9]
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity.

Oncoimmunology. 2022

[10]
Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma.

Theranostics. 2022

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索